Recently, STC-15, an inhibitor of the m6A writer METTL3, has become the first RNA-modifying enzyme inhibitor to enter clinical trials (NCT05584111) for cancer treatment (Medicine NLo, 2022). Here, METTL3 is linked to cancer.